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Insulin-like growth factor binding protein-2 (IGFBP-2) is the predominant IGF binding protein produced during adipogenesis and
is known to increase the insulin-stimulated glucose uptake (GU) in myotubes. We investigated the IGFBP-2-induced changes in
basal and insulin-stimulated GU in adipocytes and the underlying mechanisms. We further determined the role of insulin and
IGF-1 receptors in mediating the IGFBP-2 and the impact of IGFBP-2 on the IGF-1-induced GU. Fully differentiated 3T3-L1
adipocytes were treated with IGFBP-2 in the presence and absence of insulin and IGF-1. Insulin, IGF-1, and IGFBP-2 induced a
dose-dependent increase in GU. IGFBP-2 increased the insulin-induced GU after long-term incubation. The IGFBP-2-induced
impact on GU was neither affected by insulin or IGF-1 receptor blockage nor by insulin receptor knockdown. IGFBP-2
significantly increased the phosphorylation of PI3K, Akt, AMPK, TBC1D1, and PKCζ/λ and induced GLUT-4 translocation.
Moreover, inhibition of PI3K and AMPK significantly reduced IGFBP-2-stimulated GU. In conclusion, IGFBP-2 stimulates GU
in 3T3-L1 adipocytes through activation of PI3K/Akt, AMPK/TBC1D1, and PI3K/PKCζ/λ/GLUT-4 signaling. The stimulatory
effect of IGFBP-2 on GU is independent of its binding to IGF-1 and is possibly not mediated through the insulin or IGF-1
receptor. This study highlights the potential role of IGFBP-2 in glucose metabolism.
1. Introduction
Insulin-like growth factor-1 (IGF-1) bears structural homol-
ogy with proinsulin [1] and plays a key role in the prolifera-
tion and differentiation of adipocytes [2]. In vitro, it is known
to exert mitogenic effects at nanomolar concentrations [3]
and to induce insulin-like metabolic effects in both muscle
and adipose tissues [4]. The production and secretion of
IGF-1 is affected by age, nutritional status, and other
hormones [5]. Because of the ability of insulin to induce
hepatic growth hormone (GH) receptor gene expression [6]
and protein abundance [7], the GH-induced synthesis and
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 3035184, 13 pages
https://doi.org/10.1155/2017/3035184
release of IGF-1 is highly dependent on the hepatic insulin
sensitivity. This interplay among GH, insulin, and IGF-1 is
of key importance for metabolic and growth regulation [8].
The bioavailability of IGFs is regulated by a family of
seven structurally conserved binding proteins (IGFBPs)
[9–11]. These IGFBPs bind IGF-1 and IGF-2 but not insu-
lin [12]. The IGF-1 independent role of IGFBPs in growth
and metabolism has also been reported at least in vitro
[13, 14]. IGFBP-2 is the predominant binding protein pro-
duced during adipogenesis of white preadipocytes [15]. Both
inhibitory and stimulatory effects of IGFBP-2 on the cellular
actions of IGF-1 and IGF-2 have been reported [16, 17].
IGFBP-2 is reported to be a key regulator of metabolic
diseases, such as diabetes and obesity. Low IGFBP-2 has been
shown to be associated with higher fasting glucose levels and
reduced insulin sensitivity suggesting it as a biomarker for
identification of insulin-resistant individuals [18]. Moreover,
IGFBP-2 gene expression was downregulated in visceral
white adipose tissue of mice and its circulating levels were
reduced in obese ob/ob, db/db, and high fat-fed mice [19].
Low levels of circulating IGFBP-2 have also been reported
in obese adults [20] and children [21].
Wheatcroft and colleagues demonstrated that IGFBP-2
overexpression conferring protection against age-associated
decline in insulin sensitivity in mice [22]. Moreover, the
leptin-induced overexpression of IGFBP-2 has been shown
to reverse diabetes in insulin-resistant obese mice and hyper-
insulinemic clamp studies showed a threefold improvement
in hepatic insulin sensitivity following IGFBP-2 treatment
of ob/ob mice [23]. However, only few information exists to
date regarding the mechanisms underlying the positive
IGFBP-2-induced impact on glucose metabolism. Indeed,
IGFBP-2 has been shown to increase the insulin-stimulated
glucose uptake in myotubes [24] but nothing is known about
its impact on glucose uptake in adipocytes with respect to the
insulin or IGF-1-induced effects. We, therefore, aimed to
investigate the IGFBP-2-induced changes in both basal and
insulin-stimulated glucose uptake in 3T3-L1 adipocytes and
the underlying mechanisms. We further investigated the role
of insulin and IGF-1 receptors in mediating the IGFBP-2
and even the impact of IGFBP-2 on the IGF-1-induced
improvement in glucose uptake.
2. Materials and Methods
2.1. Reagents, Hormones, and Antibodies. IGF-1 and IGF-1
Long R3 (IGF-1 LR3) were purchased from BioVision
Inc. (Milpitas, CA, USA). IGFBP-2, Dulbecco’s Modified
Eagle Medium (DMEM), penicillin/streptomycin, and fetal
bovine serum (FBS) were purchased from Biochrom AG
(Berlin, Germany). Insulin, dexamethasone, LY294002, and
picropodophyllin (PPP) were supplied by Sigma-Aldrich
(Darmstadt, Germany). 3-Isobutyl-1-methylxanthine (IBMX),
S961, wortmannin, and Compound C were purchased from
Biomol GmbH (Hamburg, Germany), Phoenix Biotech
(Beijing, China), Merck Chemicals (Darmstadt, Germany),
and BIOZOL Diagnostica Vertrieb (Eching, Germany),
respectively. RevertAid First Strand cDNA Synthesis Kit,
SYBR Green master mix, Bicinchoninic Acid (BCA) protein
assay kit, and ECL reagent were supplied by Thermo
Fisher Scientific (Dreieich, Germany). DNA primers were
purchased from Eurogentec Deutschland GmbH (Köln,
Germany). All other chemicals were supplied by Sigma-
Aldrich (Darmstadt, Germany).
2.2. Cell Culture. The murine fibroblast cell line 3T3-L1
(ATCC, Manassas, VA, USA) was cultured in DMEM
supplemented with 4.5 g/L glucose, 10% fetal bovine serum
(FBS), 4mM glutamine, 50U/ml penicillin, and 50μg/ml
streptomycin until confluence. The cells were incubated to
differentiate into adipocytes following the method of Woody
et al. [25] with slight modifications. Briefly, 2 days post-
confluence, cells were treated with 0.5mM IBMX, 1μM
dexamethasone, and 1μM insulin supplemented DMEM
for 2 days. The cells were then maintained in 1μM insulin-
supplemented growth medium for 3 days and in growth
medium for 4 days prior to experiments.
2.3. Transfection of Insulin Receptor (INSR) siRNAs.Differen-
tiated 3T3-L1 adipocytes were transfected with control or
INSR specific siRNA (validated siRNA from Dharmacon)
using Lipofectamine RNAiMAX (Invitrogen) for 72 h. The
efficiency of transfection was assessed by using qPCR and
Western blot.
2.4. Measurement of Glucose Uptake. Glucose uptake was
assayed using the method described by Yamamoto et al.
[26]. Briefly, differentiated 3T3-L1 adipocytes were serum
starved for 4 h followed by incubation in D-glucose free
DMEM for 1 h. The adipocytes were washed with PBS
(pH 7.4) and then incubated for 30 min in Krebs-Ringer
bicarbonate buffer (KRBP) with different concentrations
of insulin, IGF-1, IGF-1 LR3 and/or IGFBP-2. IGF1 LR3
is an analogue of IGF-1 in which the glutamic acid at carbon
3 (Glu3) is replaced by arginine and contains 13 extra amino
acids to the N-terminus. It has a very low affinity towards
IGFBPs as compared to IGF-1 [27]. The rationale for using
IGF1-LR3 was to investigate whether IGFBP-2 is able to
impact the IGF-1-induced increase in glucose uptake regard-
less of its binding to IGF-1 itself. Had IGFBP-2 exerted
additive effect on the IGF-1-induced glucose uptake, it
would be imperative to scrutinize the observed effect as
due to binding or other means. In some experiments, the
adipocytes were incubated with 100nM S961 (INSR blocker)
for 2 h, 60nM PPP (IGF-1 receptor blocker) for 4 h, 100μM
LY294002 (PI3K inhibitor) for 1 h, 200nM wortmannin
(PI3K inhibitor) for 30min, or 200μM Compound C
(AMPK inhibitor) for 20min before the treatment. The
adipocytes were treated with [3H] 2-Deoxy-D-glucose
(0.5μCi/ml in HEPES) for 10min at room temperature
(RT) and then washed with PBS. Thereafter, the cells were
lysed in 50mM NaOH/1% Triton X-100 for scintillation
counting using a liquid scintillation counter (PerkinElmer
Wallac GmbH, Freiburg, Germany). Each experiment was
performed with three technical replicates and total number
of experiments was three.
2.5. Quantitative Reverse Transcriptase-Polymerase Chain
Reaction (qRT-PCR) Analysis. Total RNA was isolated from
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3T3-L1 adipocytes using TRizol reagent and was treated with
DNase I. RNA was quantified at 260nm using a NanoDrop
(Peqlab Biotechnologie, Erlangen, Germany) and samples
with A260/A280 ratios< 1.8 were discarded. 1μg RNA was
reverse transcribed into cDNA using RevertAid First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific, Dreieich,
Germany). cDNA was amplified using SYBR Green master
mix (Thermo Fisher Scientific, Dreieich, Germany) with the
primers set outlined in Table 1 and with the following condi-
tions: initial denaturation step at 95°C for 10min, followed by
40 cycles of 15 sec at 95°C, 60 sec at annealing temperature of
respective primer, and 60 sec at 72°C for extension. Melting
curve analysis was used to assess the quality of PCR products
and the cycle threshold (CT) values were analyzed using the
2−ΔΔCt method. Data were normalized to 36B4 and presented
as % of control.
2.6. Preparation of a Plasma Membrane Fraction for Glucose
Transporter (GLUT)-4 Translocation Assay. The amount of
GLUT-4 in the cell membranes was determined using sub-
cellular fractionation [28] followed by Western blotting
analysis. Adipocytes were washed 3 times with ice-cold
HEPES-EDTA-sucrose (HES) buffer (pH7.4) containing
proteinase inhibitors. The cell suspension was homogenized
by passing through 22-gauge needles 10 times on ice. The
homogenate was centrifuged at 16000g for 30min at 4°C,
and the pellet was suspended in HES buffer followed by
centrifugation at 16000g for 30min at 4°C. The pellet was
resuspended in HES buffer, layered on the top of sucrose
cushion (38.5% sucrose, 20mM HEPES and 1mM EDTA,
pH7) in 1 : 1 volume ratio, and centrifuged at 100000g for
1 h at 4°C. The plasma membrane fraction (middle layer)
was carefully collected and centrifuged at 40000g for 20min
at 4°C. The pellet was used to determine the amount of
GLUT-4 using Western blotting.
2.7. Western Blot Analysis. Treated 3T3-L1 adipocytes were
lysed in RIPA buffer supplemented with inhibitors for
proteinases and phosphatases. For the GLUT-4 translocation
experiments, the samples were lysed in a specific buffer
(10mM Tris-HCl [pH7.2], 150mM NaCl, 5mM EDTA,
1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS)
supplemented with proteinase and phosphatase inhibitors.
The protein content in the samples was measured by BCA
assay kit. Proteins (30–50μg) were denatured and resolved
in 10% SDS/PAGE and transferred to nitrocellulose mem-
branes. For GLUT-4, 8% SDS/PAGE was used. Blots were
blocked for 1 h and probed with 1 : 1000 diluted primary
antibodies for phosphoinositide 3-kinase (PI3K) p85, phos-
pho-(Tyr) PI3K p85, protein kinase B (Akt), phospho-Akt
(Ser473), AMP-activated protein kinase alpha (AMPKα),
phospho-AMPKα (Thr172), atypical protein kinase (PKCζ),
phospho-PKCζ/λ (Thr410/403), TBC1D1 (tre-2/USP6, BUB2,
cdc16 domain family member 1), phospho-TBC1D1 (Ser237),
and GAPDH overnight at 4°C and with GLUT-4 antibody
and Na+/K+-ATPase for 1 h at RT. The blots were washed
and incubated with 1 : 2000 diluted corresponding horse-
radish peroxidase- (HRP-) labeled secondary antibodies.
Details of the used antibodies are listed in Table 2. After
washing, the membranes were developed with an ECL
reagent and visualized and densitometry analysis using
Image Lab™ Software (Bio-Rad Laboratories GmbH,
Munich, Germany) was used to quantify protein signal.
2.8. Statistical Analysis. Data were analyzed for statistical
significance by one-way analysis of variance (ANOVA) with
Tukey’s post hoc test using GraphPad Prism 5 (La Jolla,
CA, USA). The results were presented as means± standard
error of the mean (SEM) with values of P < 0 05 were
considered significant.
3. Results
3.1. Effect of IGFBP-2 on Basal as well as Insulin and IGF-1-
Induced Increase in Glucose Uptake in 3T3-L1 Adipocytes.
To study the effect of insulin, IGF-1, IGF-1 LR3, and
IGFBP-2 on glucose uptake in 3T3-L1 adipocytes, the
cells were incubated with different concentrations of all
tested agents for 30min and [3H] 2-Deoxy-D-glucose
uptake was assayed. Insulin and IGF-1 were able to exert
statistically significant effects on glucose uptake. As repre-
sented in Figure 1(a), different concentrations of insulin
(10, 20, 50, and 100nM) were able to exert a significant
(P < 0 001) increase in glucose uptake. IGF-1 as well pro-
duced a significant increase in glucose uptake at either
10 nM (P < 0 05) or higher concentrations (P < 0 001) as
depicted in Figure 1(b).
Treatment of the cells with the lengthened analogue
of IGF-1, IGF-1 LR3, induced significant increase in glu-
cose uptake first at higher concentrations (20, 50, and
100 nM) (Figure 1(c)). Similarly, IGFBP-2 was able to sig-
nificantly (P < 0 01) increase glucose uptake in adipocytes
first at a concentration of 100nM as compared to control
cells (Figure 1(d)).
Next, we determined both the short- and long-term
impact of IGFBP-2 on insulin, IGF-1, and IGF-1 LR3-
induced glucose uptake in adipocytes.
Short-term incubation of the cells with 1 : 1 stoichio-
metric ratio of IGFBP-2 and either insulin, IGF-1, or
IGF-1 LR3 for 30min resulted in no additive increase in
glucose uptake when compared to insulin, IGF-1, or IGF-1
LR3 alone (Figure 1(e)).
Long-term incubation (24 h) of the cells with IGFBP-2
significantly (P < 0 05) increased basal glucose uptake and
exerted an additive effect (P < 0 01) on insulin-stimulated
glucose uptake. However, adipocytes treated with IGFBP-2
for 24 h showed nonsignificant changes in either IGF-1 or
IGF-1 LR3-induced glucose uptake (Figure 1(f)).
Table 1: Primers used for qRT-PCR.
Gene Sequence (5′-3′)
INSR
F: GTACTGGGAGAGGCAAGCAG
R: ACTGGCCGAGTCGTCATACT
36B4
F: TCATCCAGCAGGTGTTTGACA
R: GGCACCGAGGCAACAGTT
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3.2. The IGFBP-2-Induced Impact on Glucose Uptake Is Not
Mediated through the Activation of Insulin or IGF-1
Receptor. To investigate whether the stimulatory effect of
IGFBP-2 on glucose uptake is mediated through its binding
to insulin or IGF-1 receptors, we incubated 3T3-L1 adipo-
cytes with either insulin receptor blocker (S961) or IGF-1
receptor blocker (PPP).
3T3-L1 adipocytes incubated for 2 h with S961 showed
a significant (P < 0 05) decrease in basal glucose uptake
when compared with the control cells (Figure 2(a)). The
insulin receptor blocker S961 significantly reduced insulin
(P < 0 001), IGF-1 (P < 0 001), and IGF-1 LR3 (P < 0 01)
and stimulated glucose uptake, whereas no impact (P > 0 05)
of such treatment on IGFBP-2-stimulated glucose uptake
was seen.
When compared with S961, the IGF-1 receptor blocker
PPP was not able to induce any significant (P > 0 05) effect
on glucose uptake in adipocytes neither under basal condi-
tions nor following stimulation with IGF-1, IGF-1 LR3, or
IGFBP-2 (Figure 2(b)).
In 3T3-L1 adipocytes transfected with control or INSR-
specific siRNA (Figures 2(c) and 2(d)), insulin (Figure 2(e))
and IGF-1-stimulated glucose uptake (Figure 2(f)) were
significantly (P < 0 05) reduced, whereas INSR knockdown
potentiated the effect of IGFBP-2 on glucose uptake when
compared with the control cells (P < 0 01) (Figure 2(g)).
3.3. IGFBP-2 Stimulates Glucose Uptake in a PI3K-Dependent
Manner. Adipocytes treated with insulin and IGF-1 for
30min exhibited significant (P < 0 001) increase in PI3K
phosphorylation when compared with the control cells.
Similarly, IGFBP-2 induced a significant increase in PI3K
phosphorylation in 3T3-L1 adipocytes treated for either
30min (P < 0 01) or 24hr (P < 0 001) (Figure 3(a)).
The effect of PI3K inhibitors (LY294002 and wortman-
nin) on glucose uptake was investigated to further determine
the role of PI3K in mediating the IGFBP-2-stimulated
glucose uptake in 3T3-L1 adipocytes. Treatment of the
adipocytes with either LY294002 (Figure 3(b)) or wortman-
nin (Figure 3(c)) induced a significant decline in basal as
well as insulin-, IGF-1-, and IGFBP-2-stimulated glucose
uptake (P < 0 001).
3.4. IGFBP-2 Induces Akt and AMPK Phosphorylation and
the Subsequent Increase in GLUT-4 Translocation in a
PI3K-Dependent Manner.We further investigated the impact
of IGFBP-2 on Akt and AMPK phosphorylation as well as
on GLUT-4 translocation. As expected, insulin and IGF-1
significantly (P < 0 001) upregulated Akt phosphorylation
in treated 3T3-L1 adipocytes. Similarly, IGFBP-2 induced
a noticeable increase in Akt phosphorylation in 3T3-L1
adipocytes treated for either 30min (P < 0 05) or 24 h
(P < 0 01) (Figure 4(a)).
IGF-1 significantly (P < 0 001) increased, whereas insulin
failed to induce (P > 0 05) AMPK phosphorylation in 3T3-L1
adipocytes (Figure 4(b)). Similarly, treatment of adipocytes
with IGFBP-2 for either 30min or 24 h induced a significant
(P < 0 001) increase in AMPK phosphorylation.
To further confirm the involvement of AMPK phos-
phorylation in IGFBP-2-stimulated glucose uptake, adi-
pocytes were treated with IGFBP-2 with or without
previous incubation with the AMPK inhibitor Compound
C. Treatment of the 3T3-L1 adipocytes with IGFBP-2 sig-
nificantly (P < 0 01) increased glucose uptake, an effect
that was significantly (P < 0 001) abolished by Compound
C (Figure 3(c)).
Insulin and IGF-1 stimulation increased TBC1D1 phos-
phorylation significantly (P < 0 05) when compared with
the control adipocytes (Figure 4(d)). Similarly, treatment of
the 3T3-L1 adipocytes with IGFBP-2 for either 30min or
24 h induced a significant (P < 0 05) increase in TBC1D1
phosphorylation (Figure 4(d)).
GLUT-4 translocation was assessed by subcellular
fractionation followed by Western blotting. Treatment of
Table 2: List of antibodies used.
Antibody Species Supplier Catalog number
Anti-Phospho-AMPKα (Thr172) Rabbit Cell Signaling Technology 2535
Anti-AMPKα Rabbit Cell Signaling Technology 2532
Anti-Phospho-Akt (Ser473) Rabbit Cell Signaling Technology 9271
Anti-Akt Rabbit Cell Signaling Technology 9272
Anti-Phospho-(Tyr) p85 PI3K Rabbit Cell Signaling Technology 3821
Anti-PI3K p85 Rabbit Cell Signaling Technology 4292
Anti-Phospho-TBC1D1 (Ser237) Rabbit Millipore 07–2268
Anti-TBC1D1 Rabbit Cell Signaling Technology 5929
Anti-Phospho-PKCζ/λ (Thr410/403) Rabbit Cell Signaling Technology 9378
Anti-PKCζ Mouse Santa Cruz Biotechnology SC-17781
Anti-GLUT-4 Rabbit Sigma G4173
Anti-Na+, K+-ATPase Rabbit Cell Signaling Technology 3010
Anti-GAPDH Rabbit Cell Signaling Technology 2118
Goat anti-rabbit IgG HRP-linked Goat Cell Signaling Technology 4074
Horse anti-mouse IgG HRP-linked Horse Cell Signaling Technology 4076
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Figure 1: Effects of IGFBP-2 on insulin and IGF-1-stimulated glucose uptake in 3T3-L1 adipocytes. (a–d) Dose-dependent effects of
insulin, IGF-1, IGF-1 LR3, and IGFBP-2 on glucose uptake in 3T3-L1 adipocytes. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 versus
control. (e and f) Effect of IGFBP-2 (100 nM) (black bars) on basal and insulin (20 nM), IGF-1 (20 nM), and IGF-1 LR3 (20 nM)-induced
glucose uptake (white bars) after short- and long-term incubations. ∗P < 0 05 and ∗∗P < 0 01. Each experiment was performed with three
technical replicates and total number of experiments was three. The glucose uptake values are percentage of the controls. The results are
presented as mean± SEM.
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the adipocytes with insulin significantly (P < 0 01) stimulated
GLUT-4 translocation from the cytoplasm to the plasma
membrane. IGF-1 was also able to significantly (P < 0 05)
stimulate GLUT-4 translocation. Similarly, IGFBP-2 induced
a significant (P < 0 05) increase in GLUT-4 translocation in
treated 3T3-L1 adipocytes (Figure 4(e)).
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Figure 2: IGFBP-2 stimulates glucose uptake in insulin receptor and IGF-1 receptor-independent mechanism. (a) Effect of the insulin
receptor (INSR) blocker S961 (black bars) on basal and insulin, IGF-1, IGF-1 LR3, and IGFBP-2-induced glucose uptake (white bars).
(b) Effect of the IGF-1 receptor blocker PPP (black bars) on basal and insulin, IGF-1, IGF-1 LR3, and IGFBP-2 induced glucose uptake
(white bars). Differentiated 3T3-L1 adipocytes were incubated with 100 nM S961 for 2 h or 60 nM PPP for 4 h before treatment with
insulin, IGF-1, IGF-1 LR3, or IGFBP-2 for 30min. (c and d) Relative mRNA expression, normalized to 36B4, and Western blot analysis
of INSR following siRNA transfection, respectively. (e, f, and g) Effect of 30min treatment with insulin, IGF-1, and IGFBP-2 on glucose
uptake in control siRNA and INSR siRNA transfected 3T3-L1 adipocytes. Each experiment was performed with three technical replicates
and total number of experiments was three. The glucose uptake values are percentage of the controls. The results are presented as
mean± SEM. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001.
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3.5. IGFBP-2 Stimulates PKCζ/λ Thr410/403 Phosphorylation
in 3T3-L1 Adipocytes. A significant increase in the phosphor-
ylated levels of the PKCζ/λ isoform was seen after stimula-
tion with insulin (P < 0 05) or IGF-1 (P < 0 01) (Figure 5).
Similarly, treatment of the cells with IGFBP-2 induced a
significant increase in PKCζ/λ phosphorylation after either
30min (P < 0 01) or 24h (P < 0 001) (Figure 5).
4. Discussion
Previous studies have indicated the role of IGFBP-2 in adipo-
genesis and lipogenesis, but its effects on basal glucose uptake
and the underlying mechanistic pathways have not yet been
addressed. We, herein, provide the first evidence for insulin
and IGF-1 independent positive impact of IGFBP-2 on
glucose uptake in adipocytes. We further show that the effect
of IGFBP-2 on glucose uptake is mediated through the
activation of PI3K/Akt and AMPK pathways. Finally, we
show that the IGF-1 receptor is neither involved in the
IGF-1-induced nor in the IGFBP-2-induced increase in
glucose uptake.
Insulin and IGF-1 exerted significant dose-dependent
effects on glucose uptake in 3T3-L1 adipocytes. These
findings are in agreement with the reports from different
previous studies [29–33]. Multiple in vivo studies reported
the role of IGF-1 in enhancing insulin sensitivity and glucose
metabolism. A low-serum level of IGF-1 has been associated
with insulin resistance, and treatment with recombinant
IGF-1 has been shown to improve insulin sensitivity and
glucose metabolism [34, 35]. A study by Arafat et al. [36]
revealed that long-term treatment of GH-deficient patients
with low-dose GH results in improved insulin sensitivity
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and enhanced glucose metabolism. This improvement in
insulin sensitivity is believed to be mediated by IGF-1, which
is secreted as a result of GH stimulation. In another clinical
study, IGF-1 combined with IGFBP-3 has been shown to
improve insulin sensitivity and to reduce complications asso-
ciated with insulin resistance in HIV/AIDS patients on anti-
retroviral therapy [37]. Blocking the insulin receptor with
S961 or knocking down the INSR using siRNA significantly
reduced basal and insulin-stimulated glucose uptake. The
mechanisms behind the effect of S961 on basal glucose
uptake in 3T3-L1 are not known so far. However, our results
were concordant with previously reported impact of S961 on
insulin-stimulated glucose uptake in 3T3-L1 adipocytes
[38, 39]. Despite the fact that insulin and IGF-1 have different
affinities to INSR and IGF-1R, they are able to stimulate both
receptors [40]. However, blocking the IGF-1 receptor using
PPP [41] in our present study did not affect the impact of
IGF-1 on glucose uptake, whereas blocking or even knocking
down the INSR did, pointing to the role of INSR in mediating
these IGF-1 effects. In the study of Girnita et al. [41], PPP
efficiently blocked IGF-1R activity and reduced phosphoryla-
tion of Akt and extracellular signal-regulated kinase 1 and 2
(Erk1/2) in cultured IGF-1R-positive tumor cells. In an
in vitro kinase assay, PPP did not affect the INSR or compete
with ATP [41]. Our findings are also supported by various
reports that demonstrated a dramatic increase in INSR and
a decrease in IGF-1R during the transition from preadipo-
cytes to adipocytes in the 3T3-L1 cell line [42–45].
IGF-1-dependent and independent effects of IGFBPs on
metabolism represent a rapidly growing field of research.
IGFBP-1 was reported to inhibit IGF-1-stimulated glucose
uptake but not insulin-stimulated glucose uptake in 3T3-L1
adipocytes [31]. IGFBP-3 can lead to insulin resistance in
3T3-L1 adipocytes as reported by Chan et al. [46]. There is
increasing evidence for the role of IGFBP-2 in regulating
normal metabolism [47]. Low-serum levels of IGFBP-2 are
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correlated with obesity [22], metabolic syndrome [18], and
type 2 diabetes [48], whereas overexpression of IGFBP-2
protects against diabetes and obesity [22, 23]. Roles of
IGFBP-2 on metabolism such as inhibition of adipogenesis
and lipogenesis [49], enhancing insulin-stimulated glucose
uptake in skeletal myotubes [50], and inhibition of preadi-
pocyte differentiation in vitro [14] have been reported.
However, the effects of IGFBP-2 on basal glucose uptake
and the mechanisms underlying its IGF-1-independent
role on glucose uptake are not well studied. Here, we
reported significantly increased glucose uptake in 3T3-L1
adipocytes treated with 100nM IGFBP-2. To our knowledge,
this is the first report to show the stimulatory effects of
IGFBP-2 on basal glucose uptake in adipocytes. In addition,
our data showed a nonsignificant effect for short- and
long-term treatment with IGFBP-2 on IGF-1 and IGF-1
LR3-stimulated glucose uptake. Adipocytes treated with
IGFBP-2 for 24h followed by 30min stimulation with
IGF-1 showed a trend increase in glucose uptake. Increased
basal glucose uptake in control cells incubated with
IGFBP-2 for 24h may explain this increase. However,
incubation with IGFBP-2 for 24h exerted a significant
additive effect on the insulin-stimulated glucose uptake
which coincides with the study of Yau et al. [50] who
reported similar effect for IGFBP-2 in human skeletal
muscle cells in vitro. It can be postulated that the additive
increase in the acute insulin-induced stimulation of glucose
uptake after long-term treatment with IGFBP-2 is due to
the impact of IGFBP-2 on basal glucose uptake that is likely
also mediated through different signaling pathways other
than the PI3K/Akt pathway. Moreover, these findings pro-
vide a notion that IGFBP-2 binding to IGF-1 does not inhibit
IGF-1 from exerting its biological role, at least on glucose
uptake in vitro.
In addition to its ability to bind and modulate the
activity of IGFs, IGFBP-2 can bind to proteoglycans [51]
through two heparin-binding domains (HBDs) as well as
to integrins through its integrin-binding motif, Gly-Arg-
Asp (RGD) [51, 52]. This may explain, at least in part,
the IGFR-independent IGFBP-2 activities [49].
Interestingly, neither S961 nor PPP blocked the stimula-
tory effect of IGFBP-2 on glucose uptake. Moreover, INSR
knockdown even increased IGFBP-2-induced increase in
glucose uptake. These findings indicate the involvement of
other receptors or pathways in IGFBP-2-stimulated glucose
uptake in 3T3-L1 adipocytes. This is concordant with the
findings of Xi et al. [53], who reported that IGFBP-2
stimulates AMPK via its own receptor.
Signaling via INSR and IGF-1R shares many common
signaling pathways at target cells. One of the common
pathways in mediating glucose uptake and metabolism is
the PI3K pathway [40, 54]. Insulin and IGF-1 are known to
stimulate the activity of PI3K by triggering its phosphoryla-
tion at specific tyrosine residues by upstream components
of the INSR and IGF-1R signaling pathways [55]. In the
present study, the PI3K inhibitors, LY294002 and wortman-
nin, reduced basal and insulin, IGF-1, and even IGFBP-2-
stimulated glucose uptake in adipocytes, pointing to the role
of PI3K pathway in mediating the IGFBP-2 effect on glucose
uptake. We, therefore, investigated the impact of short- and
long-term treatment with IGFBP-2 on PI3K phosphorylation
in 3T3-L1 adipocytes, using insulin and IGF-1 as controls.
As expected, treatment of the adipocytes with either insu-
lin or IGF-1 significantly increased PI3K phosphorylation.
Similarly, IGFBP-2 induced marked increase in PI3K phos-
phorylation after both short- and long-term treatment, con-
firming the involvement of PI3K activation in mediating
IGFBP-2 effects.
Given that IGFBP-2 activates PI3K, we tested its effect on
the downstream signaling molecules Akt and AMPK and
GLUT-4 translocation. As a result of PI3K activation, insulin
and IGF-1 stimulated the phosphorylation of Akt. These
findings are in agreement with the studies of Karlsson et al.
[56] and Zhang et al. [57]. Moreover, IGF-1 significantly
increased AMPK phosphorylation. IGF-1 has been previ-
ously shown to stimulate the phosphorylation of AMPK at
its alpha subunit [58]. On the other hand, insulin did not
affect the level of p-AMPK indicating that insulin mainly
uses the PI3K pathway to exert its effects on glucose metabo-
lism. Our findings are in agreement with Shen et al. [59] who
clearly showed that insulin does not stimulate AMPK. In the
same context, pharmacological activation of AMPK increases
glucose uptake in skeletal muscles of subjects with type 2
diabetes [60] by an insulin-independent mechanism [61].
Similarly, IGFBP-2 produced a significant increase in Akt
phosphorylation which is attributed to its stimulatory effect
on PI3K. Concordant data were reported by Yau et al. [50]
in human skeletal muscle cells. The surface proteoglycan
receptor-type protein tyrosine phosphatase β (RPTPβ) has
been identified as a functionally active cell surface receptor
that links IGFBP-2 and the activation of Akt [62]. IGFBP-2
binds RPTPβ through its HBD, resulting in inhibition of
RPTPβ phosphatase activity and subsequently phosphatase
and tensin homolog (PTEN) suppression [62]. PTEN is
known to prevent Akt activation by dephosphorylating
phosphatidylinositol-3,4,5-triphosphate (PIP3). The study
of Shen et al. [62] showed that IGFBP-2−/− mice had
increased RPTPβ activity and impaired Akt activation,
changes that were reversed by administration of IGFBP-2.
In addition, both short- and long-term treatment of the
adipocytes with IGFBP-2 induced a significant increase in
AMPK phosphorylation. IGFBP-2 and IGF-1 have been
recently reported by Xi et al. [53] to induce stimulatory
effects on AMPK in osteoblasts. Our results were further
confirmed through testing the effect of AMPK inhibitor,
Compound C, on IGFBP-2-stimulated glucose uptake. Incu-
bation of the adipocytes with Compound C significantly
abolished IGFBP-2-induced glucose uptake. Taken together,
AMPK activation plays a potential role in mediating
IGFBP-2-stimulated glucose uptake in 3T3-L1 adipocytes.
One of the major metabolic changes elicited by AMPK
activation is the promotion of glucose uptake [63]. AMPK
induces glucose uptake either acutely through GLUT-4 trans-
location or in the longer term via upregulation of GLUT-4
expression [63]. Here, we show that treatment of the
3T3-L1 adipocytes with IGFBP-2 for 30min stimulates
GLUT-4 translocation to the plasma membrane. This effect
is attributed to the ability of IGFBP-2 to activate AMPK. In
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addition, we show a significant increase in the phosphoryla-
tion of the Rab-GAP protein TBC1D1 by IGFBP-2. There-
fore, the mechanism underlying the IGFBP-2 impact on
GLUT-4 translocation and the subsequent promotion of
glucose uptake involves the phosphorylation of TBC1D1 at
least partly through AMPK-pathway activation. This effect
is similar to the complementary regulation of TBC1D1 by
insulin and AMPK activators [64, 65]. Increased TBC1D1
phosphorylation and GLUT-4 translocation by IGFBP-2
could also be directly mediated by Akt activation. In the
skeletal muscle of rodents, Akt phosphorylates TBC1D1
[66] which promotes the hydrolysis of guanosine-5′-tri-
phosphate on GLUT-4-containing vesicles [67].
The atypical protein kinase PKCζ/λ/GLUT-4 is another
signaling pathway we thought to have a role in mediating
the positive effect of IGFBP-2 on glucose uptake in adipo-
cytes. In our study, insulin, IGF-1, and IGFBP-2 induced
a significant increase in PKCζ/λ phosphorylation. Since,
PKCζ/λ is dependent on PI3K activation [29, 68], it was
expected to be activated in adipocytes treated with insulin,
IGF-1, and IGFBP-2 because of their ability to activate
PI3K. Following activation, PI3K signaling diverges into
Akt-dependent and PKCζ/λ-mediated pathways [69].
PKCζ/λ is known to play little or no role in mediating
insulin effects on glucose uptake in 3T3-L1 adipocytes
[70], which may explain the IGFBP-2-induced additive
increase in the insulin-induced glucose uptake after long-
term treatment in our present study. However, further
studies using inhibitors or gene silencing are needed to
explore the precise involvement of PKCζ/λ in mediating
the IGFBP-2-induced increase in glucose uptake and
GLUT-4 translocation. One of the limitations of our study
was the IGFBP-2 concentrations used to elicit a significant
impact on glucose uptake. IGFBP-2 increased glucose uptake
at concentrations 7–10-fold higher than those described in
humans. Therefore, further in vivo studies are needed to
explore the precise impact of physiological concentrations
of IGFBP-2 on glucose utilization in humans.
In summary, this study shows that IGFBP-2 stimulates
glucose uptake in 3T3-L1 adipocytes and that synergistic
activation of Akt and AMPK mediates the modulatory effect
of IGFBP-2. The PI3K/PKCζ/λ/GLUT-4 signaling is here
shown to mediate the IGFBP-2-induced increase in glucose
uptake. Furthermore, we showed that IGFBP-2-induced
glucose uptake is independent of its binding to IGF-1, INSR,
and IGF-1R. Our findings highly strengthen the potential
and novel role for IGFBP-2 in glucose metabolism.
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